The European Medicines Agency (EMA) is offering a series of interactive Q&A clinics dedicated to the eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service. The upcoming session is scheduled for November 18, 2025, from 14:00 to 15:00 CET, and will be conducted online, allowing participants from various locations to engage directly with EMA’s regulatory data management team.
Focus and Objectives of the Session
This Q&A clinic aims to provide comprehensive support and clarity on the functionalities of the XEVMPD service. Attendees will have the opportunity to ask specific questions about substance, organisation, and referential management services, ensuring they can effectively utilize the EMA’s regulatory tools. The session will also cover updates and best practices, enhancing the overall user experience.
Ongoing Support and Accessibility
EMA plans to continue these monthly Q&A sessions until the end of 2025, demonstrating a long-term commitment to user support and engagement. In addition to the main XEVMPD service, dedicated clinics for Substance, Organisation, and Referentials Management Services will also be available, addressing the diverse needs of stakeholders. Registration for the upcoming event is open and can be completed through the EMA’s official website.
- Ensures continuous user support with monthly sessions
- Provides recorded videos post-event for broader accessibility
- Covers specific regulatory areas to address diverse user needs
- Facilitates direct interaction with EMA experts
The EMA’s initiative to host these Q&A clinics reflects its dedication to enhancing regulatory processes and user experience. By offering regular, focused sessions, the agency ensures that stakeholders remain informed and capable of navigating the complexities of medicinal product regulation effectively.
Participants are encouraged to take advantage of these sessions to deepen their understanding of the XEVMPD service and related regulatory frameworks. This proactive approach not only supports current users but also fosters a collaborative environment for future advancements in medicinal product management.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
